Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
|Yong Chan Lee||
Professor of Medicine
Director, Gastrointestinal Research Laboratory
Veterans Affairs Medical Center, Univ. California San Francisco
San Francisco, USA
|Jong Pil Im||Seoul National University College of Medicine, Seoul, Korea|
|Robert S. Bresalier||University of Texas M. D. Anderson Cancer Center, Houston, USA|
|Steven H. Itzkowitz||Mount Sinai Medical Center, NY, USA|
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Review ㅣ 2012-04-29 550 2507 3072
Laura M. Stinton, and Eldon A. Shaffer
Abstract : Diseases of the gallbladder are common and costly. The best epidemiological screening method to accurately determine point prevalence of gallstone disease is ultrasonography. Many risk factors for cholesterol gallstone formation are not modifiable such as ethnic background, increasing age, female gender and family history or genetics. Conversely, the modifi able risks for cholesterol gallstones are obesity, rapid weight loss and a sedentary lifestyle. The rising epidemic of obesity and the metabolic syndrome predicts an escalation of cholesterol gallstone frequency. Risk factors for biliary sludge include pregnancy, drugs like ceftiaxone, octreotide and thiazide diuretics, and total parenteral nutrition or fasting. Diseases like cirrhosis, chronic hemolysis and ileal Crohn’s disease are risk factors for black pigment stones. Gallstone disease in childhood, once considered rare, has become increasingly recognized with similar risk factors as those in adults, particularly obesity. Gallbladder cancer is uncommon in developed countries. In the U.S., it accounts for only ~ 5,000 cases per year. Elsewhere, high incidence rates occur in North and South American Indians. Other than ethnicity and female gender, additional risk factors for gallbladder cancer include cholelithiasis, advancing age, chronic infl ammatory conditions affecting the gallbladder, congenital biliary abnormalities, and diagnostic confusion over gallbladder polyps.
Original Article ㅣ 2022-03-15 7 1627 1537
Yuna Kim1,2 , Eugene Han3 , Jae Seung Lee1,2,4 , Hye Won Lee1,2,4 , Beom Kyung Kim1,2,4 , Mi Kyung Kim3 , Hye Soon Kim3 , Jun Yong Park1,2,4 , Do Young Kim1,2,4 , Sang Hoon Ahn1,2,4 , Byung-Wan Lee1,5 , Eun Seok Kang1,5 , Bong-Soo Cha1,5 , Yong-ho Lee1,5 , Seung Up Kim1,2,4
Abstract : Background/Aims: Nonalcoholic fatty liver disease (NAFLD) and obesity are independently associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality in patients with NAFLD. Many NAFLD patients are lean, but their ASCVD risk compared to obese subjects with NAFLD is unclear. Methods: Data from the 2008 to 2011 Korea National Health and Nutrition Examination Surveys database were analyzed (n=4,786). NAFLD was defined as a comprehensive NAFLD score ≥40 or a liver fat score ≥–0.640. ASCVD risk was evaluated using the American College of Cardiology/ American Heart Association guidelines. Results: The frequency of subjects without NAFLD, with obese NAFLD, and with lean NAFLD was 62.4% (n=2,987), 26.6% (n=1,274), and 11.0% (n=525), respectively. Subjects with lean NAFLD had a significantly higher ASCVD score and prevalence of a high ASCVD risk (mean 15.6±14.0, 51.6%) than those with obese NAFLD and without NAFLD (mean 11.2±11.4, 39.8%; mean 7.9±10.9, 25.5%; all p
Review ㅣ 2020-09-15 23 1049 1328
Abstract : This review provides an update on the characteristics of nonalcoholic fatty liver disease (NAFLD), with a focus on the effects of age, sex, and body mass index. Age is a risk factor for NAFLD progression; however, extremely old patients have unique features, namely, the associations between metabolic comorbidities and NAFLD are weaker and NAFLD is not a risk factor for mortality. The prevalence of NAFLD is higher in men than in premenopausal women, whereas the reverse is true after menopause. Thus, before menopause, estrogen may have protective effects against NAFLD. Our hospital data showed that over 25% of male patients with NAFLD and almost 40% of female patients with NAFLD, especially elderly patients, were nonobese. Although histological steatosis and activity were associated with body mass index, the prevalence of nonalcoholic steatohepatitis was not. The prevalence of advanced fibrosis showed a significant sex difference. Advanced fibrosis was significantly more frequent among severely obese men but the prevalence was lower among severely obese women. This difference could be because a substantial proportion of severely obese women were premenopausal; thus, estrogen may have much stronger effects on the development of fibrosis than on obesity. Further studies are required to develop tailored management strategies.
Original Article ㅣ 2022-09-15 2 889 1624
Jongwook Yu1 , Soo Jung Park1 , Hyung Wook Kim2 , Yun Jeong Lim3 , Jihye Park1,4 , Jae Myung Cha5 , Byong Duk Ye6 , Tae Oh Kim7 , Hyun-Soo Kim8 , Hyun Seok Lee9,10 , Su Young Jung11 , Youngdoe Kim11 , Chang Hwan Choi12
Abstract : Background/Aims: Golimumab has been used for patients with ulcerative colitis (UC) since 2013. However, there is limited data on the effectiveness and safety of the real-world use of golimumab in Asian patients. Methods: This was a multicenter, prospective, observational study. We enrolled patients with moderate-to-severe UC who were administered subcutaneous golimumab at 46 medical centers between May 2014 and November 2019. The primary outcome was the effectiveness and safety of golimumab at week 22. Clinical outcomes and adverse events were assessed according to partial Mayo score at weeks 0, 2, 6, 14, and 22. Results: A total of 130 patients were included (mean age: 45.7±16.0 years). The clinical response/ remission rates at weeks 2, 6, 14, and 22 were 40.4%/22.9%, 56.0%/35.8%, 70.6%/49.5%, and 67.9%/48.6%, respectively. Based on full Mayo score at week 14, clinical response and remission rates were 84.2% and 39.5%, respectively. Mucosal healing rate was 65.8%. In multivariate analysis with logistic regression, longer disease duration was significantly associated with a higher clinical response rate (adjusted odds ratio [aOR], 1.136; 95% confidence interval [CI], 1.006 to 1.282; p=0.040 at week 6; aOR, 1.256; 95% CI, 1.049 to 1.503; p=0.013 at week 22). A higher baseline Mayo endoscopic subscore was significantly associated with a lower clinical response rate at week 6 (aOR, 0.248; 95% CI, 0.089 to 0.692; p=0.008). The incidence of adverse drug reactions was 4.6% (6/130, nine events). No serious unexpected adverse drug reactions or deaths were reported. Conclusions: Golimumab was effective and safe as an induction and maintenance treatment for Korean patients with moderate-to-severe UC.
Hye-Kyung Jung1 , Seung Joo Kang2 , Yong Chan Lee3 , Hyo-Joon Yang4 , Seon-Young Park5 , Cheol Min Shin6 , Sung Eun Kim7 , Hyun Chul Lim8 , Jie-Hyun Kim9 , Su Youn Nam10 , Woon Geon Shin11 , Jae Myung Park12 , Il Ju Choi13 , Jae Gyu Kim14 , Miyoung Choi15 , Korean College of Helicobacter and Upper Gastrointestinal Research
Gut Liver 2021;15(2):168-195
Moon Kyung Joo1 , Chan Hyuk Park2 , Joon Sung Kim3 , Jae Myung Park4 , Ji Yong Ahn5 , Bong Eun Lee6 , Jeong Hoon Lee5 , Hyo-Joon Yang7 , Yu Kyung Cho4 , Chang Seok Bang8 , Beom Jin Kim9 , Hye-Kyung Jung10 , Byung-Wook Kim3 , Yong Chan Lee11 , Korean College of Helicobacter Upper Gastrointestinal Research
Gut Liver 2020;14(6):707-726
Gut Liver 2021;15(5):646-652
Laura M. Stinton, and Eldon A. Shaffer
Gut Liver 2012;6(2):172-187
Geoffrey C. Farrell, Derrick van Rooyen, Lay Gan, and Shivrakumar Chitturi
Gut Liver 2012;6(2):149-171
Ran Xu Zhu1, Wai-Kay Seto1,2, Ching-Lung Lai2, Man-Fung Yuen2
Gut Liver 2016;10(3):332-339